Table 3.
Univariate Analysis of Candidate SNPs of CYP2D6, CYP2E1 Gene and Risk of Doxorubicin Chemotherapy Induced Severe Toxicity of Hematological Reactions in Breast Cancer Patients
| Anemia | Neutropenia | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Gene Name | Genotype | Grade≤1 | Grade >1 | OR (95% CI) | p | Grade ≤1 | Grade >1 | OR (95% CI) | p |
| SNP | (n=81) | (n=23) | value | (n=79) | (n=25) | value | |||
| CYP2D6*3 | A/A | 49 | 14 | 1 (Reference) | 48 | 15 | 1 (Reference) | ||
| rs35742686 | A/- + -/- | 32 | 9 | 0.98 (0.38-2.54) | 0.974 | 31 | 10 | 1.03 (0.41-2.58) | 0.946 |
| CYP2D6*4 | G/G | 51 | 13 | 1 (Reference) | 51 | 13 | 1 (Reference) | ||
| rs3892097 | G/A+A/A | 30 | 10 | 1.80 (0.72-4.51) | 0.203 | 28 | 12 | 1.68 (0.67-4.17) | 0.263 |
| CYP2D6*10 | C/C | 47 | 16 | 1 (Reference) | 46 | 17 | 1 (Reference) | ||
| rs1065852 | C/T+T/T | 34 | 7 | 0.60 (0.22-1.63) | 0.32 | 33 | 8 | 0.65 (0.25-1.69) | 0.385 |
| CYP2D6*17 | C/C | 50 | 12 | 1 (Reference) | 46 | 16 | 1 (Reference) | ||
| rs28371706 | C/T+T/T | 31 | 11 | 1.47 (0.58-3.75) | 0.411 | 33 | 9 | 0.78 (0.30-1.98) | 0.608 |
| CYP2E1*5B | G/G | 79 | 23 | 1 (Reference) | 77 | 25 | 1 (Reference) | ||
| rs2031920 | G/C+C/C | 2 | 0 | 0.67 (0.03-14.59) | 0.803 | 28 | 0 | 0.05 (0.03-0.90) | 0.042* |
| CYP2E1*6 | T/T | 51 | 12 | 1 (Reference) | 48 | 15 | 1 (Reference) | ||
| rs6413432 | T/A+A/A | 30 | 11 | 1.55 (0.61-3.96) | 0.352 | 31 | 10 | 1.03 (0.41-2.58) | 0.946 |
| CYP2E1*7B | G/G | 74 | 23 | 1 (Reference) | 72 | 25 | 1 (Reference) | ||
| rs6413420 | G/T+T/T | 7 | 0 | 0.21 (0.01-3.84) | 0.293 | 7 | 0 | 0.18 (0.01-3.43) | 0.26 |
| Febrile Neutropenia | Thrombocytopenia | ||||||||
| Grade ≤1 | Grade >1 | Grade ≤1 | Grade >1 | ||||||
| (n=80) | (n=24) | (n=97) | (n=7) | ||||||
| CYP2D6*3 | A/A | 45 | 18 | 1 (Reference) | 58 | 5 | 1 (reference) | ||
| rs35742686 | A/- + -/- | 35 | 6 | 0.42 (0.15-1.19) | 0.104 | 39 | 2 | 0.59 (0.10-3.22) | 0.546 |
| CYP2D6*4 | G/G | 53 | 10 | 1 (Reference) | 61 | 3 | 1 (reference) | ||
| rs3892097 | G/A+A/A | 27 | 14 | 1.85 (0.73-4.67) | 0.188 | 36 | 4 | 2.25 (0.47-10.67) | 0.303 |
| CYP2D6*10 | C/C | 44 | 19 | 1 (Reference) | 59 | 4 | 1 (reference) | ||
| rs1065852 | C/T+T/T | 36 | 5 | 0.32 (0.10-0.94) | 0.039* | 38 | 3 | 1.16 (0.24-5.49) | 0.847 |
| CYP2D6*17 | C/C | 48 | 14 | 1 (Reference) | 57 | 5 | 1 (reference) | ||
| rs28371706 | C/T+T/T | 32 | 10 | 1.07 (0.42-2.70) | 0.884 | 40 | 2 | 0.57 (0.10-3.08) | 0.514 |
| CYP2E1*5B | G/G | 78 | 24 | 1 (Reference) | 95 | 7 | 1 (reference) | ||
| rs2031920 | G/C+C/C | 2 | 0 | 0.64 (0.02-13.80) | 0.776 | 2 | 0 | 2.54 (0.11-58.02) | 0.557 |
| CYP2E1*6 | T/T | 49 | 14 | 1 (Reference) | 60 | 3 | 1 (reference) | ||
| rs6413432 | T/A+A/A | 31 | 10 | 1.12 (0.44-2.85) | 0.797 | 37 | 4 | 2.16 (0.45-10.20) | 0.33 |
| CYP2E1*7B | G/G | 73 | 24 | 1 (Reference) | 90 | 7 | 1 (reference) | ||
| rs6413420 | G/T+T/T | 7 | 0 | 0.20 (0.01-3.63) | 0.276 | 7 | 0 | 0.80 (0.04-15.49) | 0.885 |
SNP, Single nucleotide polymorphism; OR, Odds ratio; CI, Confidence interval; * indicates significance p< 0.05; p value determined based on χ2.